progenics Message Board - Msg: 15149560

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : progenics

PGNX 4.100

-9.4%

Jun 19 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (49)	1/9/2001 1:02:33 PM
From: Jim Oravetz	Read Replies (1) of 139

Progenics: Report Shows Promise For PRO 140 HIV Drug Dow Jones Newswires TARRYTOWN, N.Y. -- Progenics Pharmaceuticals Inc.'s (PGNX) HIV inhibitor PRO 140 demonstrated "broad and potent" antiviral activity in preclinical models of HIV infection. In a press release Tuesday, the biopharmaceutical company said PRO 140, an monoclonal antibody, targets CCR5, a protein that is a co-receptor for HIV entry and infection. CCR5, which under normal conditions activates certain immune system cells, is found on the surface of cell targeted by HIV. Progenics agreed to collaborate with Protein Design Labs Inc. (PDLI) to develop a humanized PRO 140 antibody. Shares of the company recently traded at $15.81, up $1.44 or 10%, on Nasdaq volume of 5,800 shares. Average volume is 67,427 shares. Company Web site: progenics.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next